Dana-Farber Cancer Institute

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Dana-Farber Cancer Institute sits in the top decile of US sponsors by registered trial count (#42 of 15,742 sponsors by registered trial count).

781 total trials 112 currently recruiting 449 completed early-phase tilt top decile by trial count

Dana-Farber Cancer Institute: 781 sponsored US clinical trials, 112 recruiting.

Dana-Farber Cancer Institute sponsors 781 registered US clinical trials on ClinicalTrials.gov, 112 of them currently recruiting, and 449 completed. 15 of these trials are in Phase 3-4 (later-stage) and 492 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 53 trials.

Top-decile sponsor footprint

Dana-Farber Cancer Institute ranks in the top decile of sponsors by registered trial count (#42 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 49/100

449 of 537 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

781 total, page 10 of 16

COMPLETED Phase 2

Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer

NCT02040857
COMPLETED NA

PET/CT-Assessment of Liver Tumor Ablation

NCT02018107
COMPLETED Phase 1

PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors

NCT02022982
COMPLETED NA

Early Changes In Multiparametric MRI In Prostate Cancer

NCT01959542
COMPLETED NA

Healthy Living After Cancer: Weight Management Pilot Study

NCT01978899
TERMINATED Phase 2

Tivozanib As Maintenance Therapy In GYN

NCT01972516
COMPLETED NA

Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma

NCT01955395
COMPLETED Phase 1

A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma

NCT01965353
TERMINATED Phase 2

GSK1120212+GSK2141795 for Cervical Cancer

NCT01958112
COMPLETED Phase 2

Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer

NCT01942837
COMPLETED NA

A Phase II, Prospective Study of MRI in the Reclassification of Men Considering Active Surveillance in Prostate Cancer

NCT01858688
TERMINATED Phase 2

Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer

NCT01912963
COMPLETED NA

Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks

NCT01844999
COMPLETED

Impact of Radiation Therapy on Breast Conservation in DCIS

NCT02248662
COMPLETED Phase 1

ARRY-380 + Trastuzuamab for Breast w/ Brain Mets

NCT01921335
COMPLETED Phase 2

Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa

NCT01796197
COMPLETED Phase 2

A Phase II Trial of Regadenoson in Sickle Cell Anemia

NCT01788631
TERMINATED Phase 2

CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma

NCT01746173
TERMINATED Early Phase 1

A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma

NCT01878708
COMPLETED Phase 1

NIR-Guided Sentinel Lymph-Node Mapping for Esophageal Cancer

NCT01808417
COMPLETED Phase 1

Dendritic Cell Activating Scaffold in Melanoma

NCT01753089
COMPLETED Phase 2

Eribulin in HER2 Negative Metastatic BrCa

NCT01827787
COMPLETED Phase 2

Sunitinib in Never-Smokers With Lung Adenocarcinoma

NCT01829217
COMPLETED Phase 2

T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)

NCT01853748
COMPLETED Phase 2

Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors

NCT01782443
COMPLETED Phase 2

Cabozantinib for Metastatic Triple Negative BrCa

NCT01738438
COMPLETED Phase 1

Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer

NCT01783587
TERMINATED Phase 2

GVAX vs. Placebo for MDS/AML After Allo HSCT

NCT01773395
COMPLETED Phase 2

FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer

NCT01747551
COMPLETED Phase 2

Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant

NCT01754389
TERMINATED Phase 2

Ponatinib for Squamous Cell Lung and Head and Neck Cancers

NCT01761747
TERMINATED NA

Feasibility Study of Enhanced MRI for Early Stage Non Small Cell Lung Cancer (NSCLC)

NCT01799135
TERMINATED Phase 1

BKM120+Abiraterone Acetate for Metastatic CRPC

NCT01741753
COMPLETED Phase 1

Cisplatin + RT for Triple Negative Breast Cancer

NCT01674842
COMPLETED NA

Healthy Directions After Lung Surgery Pilot

NCT02135211
COMPLETED

Whole-Exome Sequencing (WES) of Cancer Patients

NCT02127359
COMPLETED Phase 1

Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer

NCT01623349
COMPLETED

iCAT for Recurrent/Refractory/HR Solid Tumors

NCT01853345
COMPLETED Phase 2

Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

NCT01466036
COMPLETED NA

Serious Illness Communication Project

NCT01786811
COMPLETED Phase 2

Fulvestrant With or Without Ganetespib in HR+ Breast Cancer

NCT01560416
COMPLETED Phase 2

BKM120 For Triple Negative Breast Cancer

NCT01790932
COMPLETED NA

Young and Strong: An Education and Supportive Care Intervention Study for Young Women With Breast Cancer

NCT01647607
TERMINATED Phase 2

Ruxolitinib in Patients With Breast Cancer

NCT01562873
COMPLETED Phase 2

Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia

NCT01614821
COMPLETED Phase 2

Study of Vitamin D in Untreated Metastatic Colorectal Cancer

NCT01516216
COMPLETED Phase 1

XL-184+Abiraterone in Post-Chemo CRPC

NCT01574937
COMPLETED NA

Image-guided Breast Surgery in the Advanced Multimodality Image Guided Operating Suite (AMIGO)

NCT02057432
TERMINATED Phase 2

Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma

NCT01484314
COMPLETED Phase 2

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

NCT01494662
← Previous Page 10 of 16 Next →

Phase Distribution

PhaseTrial count
Phase 1 181
Phase 2 311
Phase 3 14
Phase 4 1

Therapeutic Areas

Breast Cancer 53
Prostate Cancer 21
Leukemia 13
Ovarian Cancer 13
Lung Cancer 11
Pancreatic Cancer 9
Myelodysplastic Syndromes 9
Multiple Myeloma 8
Head and Neck Cancer 8
Cancer 8

What is open in the Dana-Farber Cancer Institute pipeline

112 recruiting of 781 indexed (14% open); 449 completed (57%).

Phase mix: 15 late (III/IV) vs 492 early (I/II) (early-phase heavy).

Top condition: Breast Cancer (53 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Dana-Farber Cancer Institute: open-pipeline peers nationwide

Peers matched on 781 registered trials and 14% open enrollment, not the therapeutic-area sidebar.

Dana-Farber Cancer Institute sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 02004006008001,000 14%16%18%20%22% Total trials Recruiting share Dana-Farber Cancer InstituteUniversity of California, San DiegoUniversity of ChicagoMedical University of South CarolinaUniversity of UtahThe Cleveland ClinicAcademic and Community Cancer Research UnitedAdaptive BiotechnologiesAgelessRx
Dana-Farber Cancer Institute sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Dana-Farber Cancer Institute sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 781 trials (± recruiting share)

Sponsors near 14% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Dana-Farber Cancer Institute page

781 registered trials is a research-attention snapshot, not an endorsement of Dana-Farber Cancer Institute or any single study.

  • 112 of Dana-Farber Cancer Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Breast Cancer is the condition Dana-Farber Cancer Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Dana-Farber Cancer Institute pipeline card: 781 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.